Stevanato Group (NYSE:STVN) Shares Up 3.9% – What’s Next?

Stevanato Group S.p.A. (NYSE:STVN)’s stock price shot up 3.9% during trading on Tuesday . The company traded as high as €21.39 ($23.25) and last traded at €21.39 ($23.25). 126,061 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 350,071 shares. The stock had previously closed at €20.58 ($22.37).

Analysts Set New Price Targets

STVN has been the subject of several recent analyst reports. Bank of America upped their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Wolfe Research started coverage on shares of Stevanato Group in a report on Friday, December 13th. They set an “outperform” rating and a $28.00 price target for the company. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. UBS Group decreased their target price on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of €27.75 ($30.16).

Stevanato Group Stock Up 4.0 %

The firm has a 50 day moving average of €21.16 and a 200-day moving average of €20.58. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The stock has a market capitalization of $6.48 billion, a P/E ratio of 45.53, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting the consensus estimate of €0.20 ($0.22). The company had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. On average, equities research analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

A number of hedge funds have recently made changes to their positions in STVN. Royce & Associates LP increased its stake in Stevanato Group by 45.8% in the third quarter. Royce & Associates LP now owns 343,159 shares of the company’s stock valued at $6,863,000 after acquiring an additional 107,869 shares during the period. Natixis Advisors LLC grew its stake in shares of Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company’s stock valued at $1,027,000 after purchasing an additional 8,669 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Stevanato Group by 67.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 2,784,912 shares of the company’s stock worth $55,698,000 after buying an additional 1,123,104 shares in the last quarter. Lindenwold Advisors INC boosted its stake in Stevanato Group by 13.5% in the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock valued at $239,000 after buying an additional 1,415 shares in the last quarter. Finally, Raymond James Trust N.A. grew its position in Stevanato Group by 22.6% in the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock valued at $251,000 after acquiring an additional 2,317 shares during the period.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.